AFJKU
AFJKU
Aimei Health Technology Co., Ltd UnitIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd Unit's financial evolution and strategic trajectory over the past five years.
AFJKU benefits from having raised capital in public markets, operating with no conventional debt and a structure designed to bring a private company public. It has posted accounting profits thanks to non-operating items, holds a substantial base of non-current assets, and faces no immediate burden from interest payments or capital expenditure commitments. The SPAC format can be attractive to a private company seeking a faster or more flexible route to listing.
The main risks stem from the absence of a real operating business, zero revenue, and negative operating and free cash flow. Liquidity at the corporate level appears thin relative to current obligations, while shareholder equity and retained earnings are firmly negative, pointing to a fragile capital structure. Competitive and regulatory pressures in the SPAC space, the possibility of investor redemptions, and uncertainty about the eventual target all add significant execution and business risk.
The outlook is highly dependent on whether AFJKU can successfully identify, negotiate, and close a high-quality merger, and then on how that combined business performs. Until then, financial statements mainly reflect a transient SPAC structure rather than a going concern with stable revenues and cash flows. Future assessments should focus less on the current shell and more on the fundamentals, strategy, and competitive position of whatever operating company ultimately merges into AFJKU.
About Aimei Health Technology Co., Ltd Unit
https://www.aimeihealth.comAimei Health Technology Co Ltd operates as a special purpose acquisition company (SPAC), also known as a blank check company.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $61.98K ▼ | $45.44K ▼ | 0% | $0.01 ▼ | $-61.98K ▲ |
| Q4-2025 | $0 | $250.59K ▲ | $98.12K ▼ | 0% | $0.02 ▼ | $-250.59K ▼ |
| Q3-2025 | $0 | $130.15K ▲ | $352.02K ▼ | 0% | $0.06 ▼ | $-130.15K ▼ |
| Q2-2025 | $0 | $41.6K ▼ | $424.97K ▲ | 0% | $0.07 ▲ | $-41.6K ▲ |
| Q1-2025 | $0 | $413.41K | $184.66K | 0% | $0.02 | $-413.41K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $18.52K ▲ | $12.29M ▲ | $4.21M ▲ | $8.09M ▲ |
| Q4-2025 | $2.93K ▼ | $12.1M ▼ | $4.06M ▲ | $8.04M ▼ |
| Q3-2025 | $2.98K ▲ | $45.47M ▲ | $3.46M ▲ | $42M ▲ |
| Q2-2025 | $2.14K ▼ | $44.56M ▲ | $2.9M ▲ | $41.65M ▲ |
| Q1-2025 | $7.34K | $43.6M | $2.38M | $41.23M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $45.44K ▼ | $-74.61K ▼ | $-68.66K ▼ | $158.86K ▲ | $15.59K ▲ | $-74.61K ▼ |
| Q4-2025 | $98.12K ▼ | $-43.23K ▲ | $33.69M ▲ | $-33.65M ▼ | $-50 ▼ | $-43.23K ▲ |
| Q3-2025 | $352.02K ▼ | $-96.11K ▲ | $-450K | $546.95K ▼ | $841 ▲ | $-96.11K ▲ |
| Q2-2025 | $424.97K ▲ | $-201.75K ▲ | $-450K ▼ | $646.54K ▲ | $-5.21K ▲ | $-201.75K ▲ |
| Q1-2025 | $184.66K | $-224.01K | $30.79M | $-30.58M | $-20.86K | $-224.01K |
5-Year Trend Analysis
A comprehensive look at Aimei Health Technology Co., Ltd Unit's financial evolution and strategic trajectory over the past five years.
AFJKU benefits from having raised capital in public markets, operating with no conventional debt and a structure designed to bring a private company public. It has posted accounting profits thanks to non-operating items, holds a substantial base of non-current assets, and faces no immediate burden from interest payments or capital expenditure commitments. The SPAC format can be attractive to a private company seeking a faster or more flexible route to listing.
The main risks stem from the absence of a real operating business, zero revenue, and negative operating and free cash flow. Liquidity at the corporate level appears thin relative to current obligations, while shareholder equity and retained earnings are firmly negative, pointing to a fragile capital structure. Competitive and regulatory pressures in the SPAC space, the possibility of investor redemptions, and uncertainty about the eventual target all add significant execution and business risk.
The outlook is highly dependent on whether AFJKU can successfully identify, negotiate, and close a high-quality merger, and then on how that combined business performs. Until then, financial statements mainly reflect a transient SPAC structure rather than a going concern with stable revenues and cash flows. Future assessments should focus less on the current shell and more on the fundamentals, strategy, and competitive position of whatever operating company ultimately merges into AFJKU.

CEO
Junheng Xie
Compensation Summary
(Year )
Ratings Snapshot
Rating : C

